Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Sun Yat-sen University

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Breast Neoplasms

Treatments: Biological: Tumor-draining lymph node-derived lymphocyte (LNL); Procedure: Sentinel Lymph Node Biopsy (SLNB); Drug: Nab-paclitaxel; Drug: Doxorubicin; Drug: Epirubicin; Biological: Interleukin-2; Drug: Fludarabine; Drug: Cyclophosphamide

Study type: Interventional

Funder types: Other

Identifiers

NCT05981014

【2021】04-01

Details and patient eligibility

About

RATIONALE: Patients with HER2-negative breast cancer not responding to initial neoadjuvant chemotherapy might have lower chances for a pathologic complete response (pCR) at definitive surgery, indicating worse prognosis. Adoptive cell therapy has demonstrated efficacy in advanced breast cancer, but whether the addition of adoptive cell therapy to neoadjuvant chemotherapy could increase the pCR rate remains unclear. Tumor-draining lymph node-derived lymphocytes (LNLs) that have abundant tumor-reactive T cells, but not exhausted T cells, are easy to produce. It is not yet known whether LNL treatment is safe and effective in patients with HER2-negative breast cancer not responding to neoadjuvant chemotherapy.

PURPOSE: This open-label phase I/II trial is to investigate the safety and efficacy of autologous LNL in patients with HER2-negative breast cancer not responding to neoadjuvant chemotherapy.

Enrollment: 196 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

In order to be eligible for participation in this trial, the participant must:

1. Have signed the informed consent to study participation.

2. Be a female subject and aged between 18 and 70 years.

3. Provide a core needle biopsy which is histologically confirmed as invasive breast cancer. Excisional biopsy or surgical biopsy is not allowed.

4. Have received two cycles of doxorubicin or epirubicin, plus cyclophosphamide, and had stable disease (SD) confirmed by breast MRI.

5. Have breast cancer defined as the following combined primary tumor (T), regional lymph node (N), and distant metastasis (M) staging per AJCC for breast cancer staging criteria version 8 based on breast MRI assessment:

   The minimum size of the primary tumor was 1 cm in largest diameter by breast MRI, N0-3, M0.

6. Have HER2-negative breast cancer, defined as 0-1+ by immunohistochemistry or 2+ by immunohistochemistry without HER2 amplification by FISH.

7. Have known hormone receptor status (estrogen receptor [ER], progesterone receptor [PgR]), Ki67 value and, if institutional standard permits, known tumor grade.

8. Have not received prior therapies for breast cancer, including but not limited to, chemotherapy (except two cycles of doxorubicin or epirubicin, plus cyclophosphamide), radiotherapy, hormonal therapy, targeted therapy, biological therapy and surgery.

9. Have accessible tumor-draining lymph nodes by surgery to grow LNL. Participants have not received sentinel lymph node biopsy (SLNB) and ipsilateral axillary lymph node dissection (ALND) for the breast cancer lesion.

10. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

11. Demonstrate adequate normal organ function:

    NOTE: Blood component or cytokine therapy is not allowed within 14 days before surgery.

    1. Routine blood test:

       • Absolute neutrophil count (ANC) ≥1.5×10^9/L
       • Lymphocyte count (LC) >0.5×10^9/L
       • Platelets (PLT) ≥100×10^9/L
       • Hemoglobin (Hb) ≥90 g/L

    2. Liver function test:

       • AST and ALT ≤2.5 ×ULN (≤5×ULN for participants with liver metastases)
       • ALP ≤2.5 ×ULN (≤5×ULN for participants with liver or bone metastases)
       • Total bilirubin ≤1.5×ULN (≤3.0 mg/dL for participants with Gilbert's syndrome)

    3. Renal function test:

       • Calculated creatinine clearance (CrCL) ≥45 mL/min OR creatinine ≤1.5 × ULN

    4. Coagulation function test:

       • APTT ≤1.5 ×ULN
       • INR or PT ≤1.5×ULN

    5. Doppler echocardiography:

       • Left ventricular ejection fraction (LVEF) ≥50%

    6. Pulmonary function test:

       • FEV1≥60%

12. Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through one year (or longer as specified by local institutional guidelines) after the last dose of study treatment. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to LNL infusion.

13. Have recovered from prior therapy-related adverse events to Grade≤1 per CTCAE version 5.0 criteria or met the criteria of normal organ function specified above prior to the surgery for obtaining the lymph nodes, except for second-degree peripheral nerve injury, alopecia, leukoderma, hypothyroidism controlled by thyroid hormone replacement therapy, type 1 diabetes controlled by insulin therapy, and other irreversible toxic events that would not be exacerbated by LNL infusion as judged by the investigator (e.g., hearing loss).

Exclusion criteria

The participant must be excluded from participating in this trial if the participant:

1. Has metastatic breast cancer.
2. Has a known additional malignancy within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, and ductal carcinoma in situ that has undergone radical mastectomy.
3. Has a known history of cardiovascular disease, including but not limited to, (1) congestive heart failure (New York Heart Association [NYHA] functional classification Class > 2), (2) unstable angina pectoris, (3) myocardial infarction in the past 3 months, (4) supraventricular arrhythmia or ventricular arrhythmia that requires treatments.
4. Has interstitial pneumonia or active pneumonia that has clinical implications, or other respiratory diseases that seriously affect pulmonary function.
5. Has an active infection requiring systemic therapy or has an unexplained fever of >38.5℃ except fevers caused by cancer.
6. Has arterial and/or venous thrombotic events in the past 5 months, e.g., cerebrovascular accident, deep vein thrombosis or pulmonary embolism.
7. Has a known psychiatric, alcohol abuse or substance abuse disorders.
8. Is pregnant or breastfeeding.
9. Has an active autoimmune disease, a history of autoimmune disease, or autoimmune disease that has required systemic treatment (e.g., with use of prednisone at a dose of >10mg per day or other corticosteroids at an equivalent dose). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed.
10. Has a history of congenital immunodeficiency or acquired immunodeficiency (e.g., positive serology test for HIV).
11. Has tuberculosis in the past one year, or has a history of active tuberculosis more than one year but did not receive regular treatments.
12. Has known active hepatitis B or hepatitis C. Participants that are hepatitis B surface antigen (HBsAg) or hepatitis B core antigen (HBcAg) positive may participate provided that the HBV DNA level is normal. Participants that are hepatitis C antibody positive may participate provided that the HCV DNA level is normal. Carriers of HBV or HCV must receive anti-virus therapy, and take regular DNA copy number tests during this trial.
13. Has received a live vaccine within 4 weeks prior to enrollment, or plans to receive a live vaccine during this trial.
14. Has a history of allogeneic bone marrow or organ transplant.
15. Has received the study-related drugs including anthracycline, cyclophosphamide, taxane, fludarabine, interleukin-2, except two cycles of doxorubicin or epirubicin, plus cyclophosphamide.
16. Has a history of hypersensitivity or allergy to the drugs in this study and any of their components including but not limited to, LNL, doxorubicin/epirubicin, cyclophosphamide, nab-paclitaxel, fludarabine, interleukin-2, dimethyl sulphoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (β-lactam antibiotics, gentamicin).
17. Has contraindication for use of IL-2, including but not limited to, refractory or intractable epilepsy, and active gastrointestinal bleeding.
18. Has a history of Grade≥2 neuropathy.
19. Has received long half-life angiogenesis inhibitors within four weeks prior to enrollment, e.g., bevacizumab.
20. Is receiving any medication prohibited in combination with study treatments as described in the respective product labels, unless medication was stopped within 7 days prior to enrollment.
21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with participation for the full duration of the study, or render study participation not compatible with the participant's best interest, in the opinion of the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

196 participants in 2 patient groups

Phase I and phase II: Chemotherapy + LNL treatment

Experimental group

Description:

Participants in both phase I and phase II portions receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by neoadjuvant LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.

Treatment:

Drug: Nab-paclitaxel

Drug: Doxorubicin

Biological: Interleukin-2

Drug: Cyclophosphamide

Drug: Epirubicin

Procedure: Sentinel Lymph Node Biopsy (SLNB)

Drug: Cyclophosphamide

Drug: Fludarabine

Biological: Tumor-draining lymph node-derived lymphocyte (LNL)

Phase II: Chemotherapy

Active Comparator group

Description:

The single-arm phase I study did not have this arm. Participants in phase II portion receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.

Treatment:

Drug: Nab-paclitaxel

Drug: Doxorubicin

Drug: Cyclophosphamide

Drug: Epirubicin

Drug: Cyclophosphamide